Liver injury in the setting of steatosis: Crosstalk between adipokine and cytokine†
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Central to the mechanisms underlying a variety of forms of liver injury are factors produced from the accompanying inflammatory response. Liver injury triggers the recruitment and activation of macrophages and neutrophils, a process mediated in part by lipopolysaccharide.1 These activated cells produce a number of potentially injurious factors that may promote hepatocyte injury. The most critical of these is the cytokine tumor necrosis factor (TNF)-α. Through either direct toxic or proinflammatory effects, TNF may promote injury from toxins,2 ischemia/reperfusion,3 and hepatitis viruses.4 Strategies to block the production, activity, or death pathway signaling of TNF therefore represent potential therapies for a variety of liver diseases. However, while progress has been made in understanding the mechanisms of hepatocyte sensitization to TNF cytotoxicity, effective means of suppressing this effect in vivo are still lacking. BMI, body mass index; GalN, galactosamine; LPS, lipopolysaccharide; PPAR, peroxisome proliferator-activated receptor; TNF, tumor necrosis factor; TNFR, TNF receptor. Crucial to understanding liver injury in nonalcoholic fatty liver disease (NAFLD) is the delineation of mechanisms of progression from benign fatty liver to hepatocyte injury and steatohepatitis. Several facts suggest that the inflammatory response and TNF in particular may promote this liver injury. First, the disease lacks an apparent direct death stimulus such as a hepatotoxin or hypoxia, suggesting that indirect factors must cause cell injury. Second, steatohepatitis frequently occurs in the setting of obesity and insulin resistance or diabetes which are increasingly recognized as proinflammatory states with increased oxidative stress, cytokine production, and cellular stress pathway signaling.5, 6 Obesity in particular is associated with increased TNF production from fat stores. The ability of TNF to act as a hepatotoxin, and the presence of increased levels of this cytokine in conditions associated with NAFLD, make TNF a prime candidate to promote progression to steatohepatitis. This possibility is supported by studies in leptin deficient ob/ob mice with obesity and fatty liver in which TNF inhibition reduced steatosis and liver injury.7, 8 However, studies of ob/ob mice lacking type I and II TNF receptors (TNFR1 and TNFR2) have suggested that TNF is not involved in their liver disease.9 How TNF could cause steatotic cell injury is unclear because TNF is normally a mitogen unless hepatocellular resistance mechanisms to the toxic effects of TNF are somehow circumvented. One possibility is that hepatocyte sensitization to TNF injury in the setting of NAFLD results from the cellular effects of overexpression of the pro-oxidant enzyme cytochrome P450 2E1 in this disease.10 An additional factor in the regulation of liver injury occurring in the setting of obesity and insulin resistance is the influence of adipocyte produced proteins.11 Adipocytes not only store excess energy, but also respond to metabolic signals by secreting proteins that exert local, central, and peripheral effects. Principal among these adipocyte specific or enriched factors, or adipokines, are leptin, resistin, and adiponectin. Leptin has multiple actions that include decreasing food intake and increasing energy expenditure. Serum leptin levels increase in proportion with body mass index (BMI). Whether leptin levels are altered in NAFLD is controversial, with some studies demonstrating increased levels in this disease,12 but others finding no correlation between serum leptin and the development of steatohepatitis.13 Resistin is an adipocyte produced protein whose main effect is to increase hepatic glucose production.14 Serum resistin levels are increased in human obesity,15 but levels in NAFLD have not yet been examined. Thus, no clear evidence yet implicates either leptin or resistin in the development of NASH. Adiponectin is present in significant concentrations in human serum (5–30 nM), and circulates in several forms including dimers, trimers, and a high-molecular weight complex consisting of up to six trimers.16 Two adiponectin receptors, AdipoR1 and AdipoR2, have been cloned.17 Liver expresses both receptor genes and has the highest expression of AdipoR2 among organs. Adiponection is secreted by adipocytes in inverse proportion to BMI.18 Serum adiponectin levels are also reduced with insulin resistance and diabetes.19 Metabolically adiponectin acts to reduce body fat,20 improve hepatic and peripheral insulin sensitivity,21 and decrease serum fatty acid levels in association with increased fatty acid oxidation in muscle.22 However, adiponectin has significant anti-inflammatory as well as metabolic effects. Adiponectin blocks macrophage phagocytosis and lipopolysaccharide-induced TNF release in vitro, possibly through inhibition of NF-κB activation.23-25 These dual metabolic and anti-inflammatory beneficial effects of adiponectin have been utilized
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476
Cited by
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Haukeland, J. W., Damås, J. K., Konopski, Z., Løberg, E. M., Haaland, T., Goverud, I., Torjesen, P. A., Birkeland, K., Bjøro, K., & Aukrust, P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.02.011 · Cited by 603
JNK1 but not JNK2 promotes the development of steatohepatitis in mice
Schattenberg, J. M., Singh, R., Wang, Y., Lefkowitch, J. H., Rigoli, R. M., Scherer, P. E., & Czaja, M. J. (2006) · Hepatology · doi:10.1002/hep.20999 · Cited by 384
Eguchi, Y., Eguchi, T., Mizuta, T., Ide, Y., Yasutake, T., Iwakiri, R., Hisatomi, A., Ozaki, I., Yamamoto, K., Kitajima, Y., et al. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1790-5 · Cited by 272
Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., & Shibata, N. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.028 · Cited by 233
Metadata
- Authors
- Czaja, M. J.
- Venue
- Hepatology
- Published
- 2004-07
- Volume
- 40
- Issue
- 1
- Pages
- 19-22
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2080945617
- Cited by
- 71
- References
- 8
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver injury in the setting of steatosis: Crosstalk between adipokine and cytokine†. https://app.cochat.ai/papers/10.1002/hep.20328
- The paper
- Czaja, M. J. (2004). Liver injury in the setting of steatosis: Crosstalk between adipokine and cytokine†. Hepatology. https://doi.org/10.1002/hep.20328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.